NO20092274L - Ansamycinformuleringer og fremgangsmater for anvendelse derav - Google Patents

Ansamycinformuleringer og fremgangsmater for anvendelse derav

Info

Publication number
NO20092274L
NO20092274L NO20092274A NO20092274A NO20092274L NO 20092274 L NO20092274 L NO 20092274L NO 20092274 A NO20092274 A NO 20092274A NO 20092274 A NO20092274 A NO 20092274A NO 20092274 L NO20092274 L NO 20092274L
Authority
NO
Norway
Prior art keywords
methods
geldanamycin
compositions
ansamycin
formulations
Prior art date
Application number
NO20092274A
Other languages
English (en)
Inventor
Roger H Pak
Edward B Holson
James L Wright
Louis Grenier
Brian C Austad
James R Porter
John J Lee
Original Assignee
Infinity Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infinity Discovery Inc filed Critical Infinity Discovery Inc
Publication of NO20092274L publication Critical patent/NO20092274L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Det beskrives blant annet faste former av geldanamycinanaloger, farmasøytiske blandinger som omfatter en geldanamycinanalog og en krystallisasjonshemmer, fremgangsmåter for fremstilling og anvendelse av slike blandinger. Dessuten beskrives fremgangsmåter for behandling av cancer, en neoplastisk sykdomstilstand og/eller en hyperproliferativ lidelse, samt fremgangsmåter for inhibering av varmesjokkprotein 90 ("Hsp90").
NO20092274A 2006-12-12 2009-06-12 Ansamycinformuleringer og fremgangsmater for anvendelse derav NO20092274L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87434906P 2006-12-12 2006-12-12
US91447707P 2007-04-27 2007-04-27
US93991307P 2007-05-24 2007-05-24
PCT/US2007/025317 WO2008073424A2 (en) 2006-12-12 2007-12-11 Ansamycin formulations and methods of use thereof

Publications (1)

Publication Number Publication Date
NO20092274L true NO20092274L (no) 2009-08-25

Family

ID=39410222

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092274A NO20092274L (no) 2006-12-12 2009-06-12 Ansamycinformuleringer og fremgangsmater for anvendelse derav

Country Status (14)

Country Link
US (3) US7947670B2 (no)
EP (1) EP2126548A2 (no)
JP (1) JP2010512397A (no)
KR (1) KR20090098982A (no)
AR (1) AR064304A1 (no)
AU (1) AU2007332727A1 (no)
BR (1) BRPI0720277A2 (no)
CA (1) CA2672537A1 (no)
CL (1) CL2007003604A1 (no)
MX (1) MX2009006166A (no)
NO (1) NO20092274L (no)
PE (1) PE20081506A1 (no)
TW (1) TW200833666A (no)
WO (1) WO2008073424A2 (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2678124C (en) * 2003-11-17 2014-10-07 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
AU2004309395C1 (en) 2003-12-23 2012-10-04 Infinity Discovery, Inc. Analogs of benzoquinone-containing ansamycins for the treatment of cancer
WO2005118586A1 (en) * 2004-06-02 2005-12-15 Sandoz Ag Meropenem intermediate in crystalline form
US8188138B2 (en) * 2005-09-21 2012-05-29 4Sc Ag Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
BRPI0617947A2 (pt) * 2005-10-31 2011-08-09 Janssen Pharmaceutica Nv processos para a preparação de derivados de piperazinil e diazapanil benzamida
CA2656057C (en) * 2006-06-16 2012-10-02 H. Lundbeck A/S Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
CN101568544B (zh) * 2006-10-27 2016-10-26 西格诺药品有限公司 包含4‑[9‑(四氢‑呋喃‑3‑基)‑8‑(2,4,6‑三氟‑苯氨基)‑9h‑嘌呤‑2‑基氨基]‑环己烷‑1‑醇的固体形式，其组合物，及其用途
US8426396B2 (en) * 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
ES2347619B1 (es) * 2008-05-13 2011-09-15 Consejo Superior De Investigaciones Cientificas (Csic) (50%) Procedimiento para diseñar una terapia individual antitumoral basado en la deteccion de los niveles de proteina hsp90, el uso de inhibidores de la proteina hsp90 para la elaboracion de composiciones farmaceuticas, las composiciones asi obtenidas y sus aplicaciones.
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
JP5583680B2 (ja) * 2008-10-15 2014-09-03 インフィニティー ファーマスーティカルズ インコーポレイテッド アンサマイシンヒドロキノン組成物
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
CA2779843A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
PT2544679T (pt) 2010-03-12 2019-07-11 Omeros Corp Inibidores de pde-10 e composições e métodos relacionados
US20110263701A1 (en) * 2010-04-21 2011-10-27 Sigal Blau Gabapentin enacarbil compositions
CN103189360A (zh) * 2010-09-01 2013-07-03 艾尼纳制药公司 5-ht2c激动剂的非吸湿性盐
CN103930419B (zh) * 2011-09-30 2016-06-01 广东东阳光药业有限公司 阿齐沙坦的晶型及其制备方法
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
US9879002B2 (en) 2015-04-24 2018-01-30 Omeros Corporation PDE10 inhibitors and related compositions and methods
JP2018535969A (ja) 2015-11-04 2018-12-06 オメロス コーポレーション Ｐｄｅ１０阻害剤の固体状態形態
JP2017110205A (ja) * 2015-12-11 2017-06-22 日本合成化学工業株式会社 結晶成長抑制剤
SG11201907276TA (en) * 2017-02-10 2019-09-27 Altum Pharmaceuticals Inc Compositions of gallium (iii) complexes for oral administration
KR20190138871A (ko) * 2017-04-24 2019-12-16 사무스 테라퓨틱스, 인코포레이티드 Hsp90 저해제 경구 제형 및 관련 방법
JP2020533412A (ja) * 2017-09-07 2020-11-19 アセネックス エイチケイ イノベイティブ リミテッド ２−（５−（４−（２−モルホリノエトキシ）フェニル）ピリジン−２−イル）−ｎ−ベンジルアセトアミドの固体形態
GB2581154B (en) * 2019-02-05 2022-09-28 Colvistec Ag Amorphous pharmaceutical compositions
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
GB2106111B (en) 1981-09-17 1985-11-06 Takeda Chemical Industries Ltd Macbecin derivatives and their production
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
BR9207024A (pt) 1992-01-06 1995-12-05 Pfizer Processo e utilizações para 4,5-DI-hidrogeldanamicina e sua hidroquinona
US5387584A (en) 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
CA2166320A1 (en) 1993-06-29 1995-01-12 Randall James Gallaschun Ansamycin derivatives as antioncogene and anticancer agents
US5932566A (en) 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US5834472A (en) 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
WO1998008490A1 (en) 1996-09-01 1998-03-05 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
EP0901786B1 (en) 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
US6051607A (en) 1998-07-02 2000-04-18 Micro Therapeutics, Inc. Vascular embolizing compositions comprising ethyl lactate and methods for their use
CA2338000C (en) 1998-07-17 2009-12-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Water-soluble 4-thio-maleimido derivatives and methods for their production
US6188221B1 (en) 1998-08-07 2001-02-13 Van De Kop Franz Method and apparatus for transmitting electromagnetic waves and analyzing returns to locate underground fluid deposits
JP2002532535A (ja) 1998-12-22 2002-10-02 アメリカ合衆国 水不溶性薬剤送達システム
US6682758B1 (en) 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
ES2306646T3 (es) 1999-02-09 2008-11-16 Pfizer Products Inc. Composiciones de farmacos basicos con biodisponibilidad incrementada.
EP1027887B1 (en) 1999-02-10 2008-08-13 Pfizer Products Inc. Matrix controlled release device
ATE400252T1 (de) 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
JP4025545B2 (ja) 1999-07-09 2007-12-19 チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド 改善された色特性を有する顔料及びその製造方法
SE9904382D0 (sv) * 1999-12-02 1999-12-02 Siemens Elema Ab High Frequency Oscillation Patient Ventilator System
NZ513964A (en) 1999-12-08 2004-01-30 Pharmacia Corp Solid-state form of celecoxib having enhanced bioavailability
GT200100039A (es) 2000-03-16 2001-12-31 Pfizer Inhibidor de la glucogeno fosforilasa.
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US20050203612A1 (en) 2000-12-22 2005-09-15 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
US20040148232A1 (en) * 2001-01-22 2004-07-29 Osamu Fushimi Electronic catalog aggregation apparatus for realizing fast and efficient electronic catalog system
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
CA2450762A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers
JP2003006555A (ja) 2001-06-25 2003-01-10 Nova:Kk コンテンツ配信方法、シナリオデータ、記録媒体およびシナリオデータ生成方法
JP4032216B2 (ja) 2001-07-12 2008-01-16 ソニー株式会社 光学多層構造体およびその製造方法、並びに光スイッチング素子および画像表示装置
EP1420747A4 (en) 2001-08-06 2010-06-02 Kosan Biosciences Inc ANSAMYCIN BENZOQUINONE
US20090197852A9 (en) 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
US6872715B2 (en) 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
JP2005504086A (ja) * 2001-09-24 2005-02-10 コンフォーマ セラピューティクス コーポレーション １７−アリルアミノゲルダナマイシン（１７−ａａｇ）および他のアンサマイシン類を製造する方法
EP1469832B2 (en) 2002-02-01 2016-10-26 Bend Research, Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
AU2003217393B8 (en) 2002-02-08 2009-06-25 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
CA2481683A1 (en) 2002-04-10 2003-10-23 Conforma Therapeutics Corporation Ansamycin formulations and methods for producing and using same
EP1605931A4 (en) 2003-03-13 2009-04-29 Conforma Therapeutics Corp MEDICINAL FORMULATIONS WITH LONG AND MEDIUM-CHAINED TRIGLYCERIDES
US20060019941A1 (en) 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
AU2004309395C1 (en) 2003-12-23 2012-10-04 Infinity Discovery, Inc. Analogs of benzoquinone-containing ansamycins for the treatment of cancer
CA2551254A1 (en) 2003-12-31 2005-07-21 Pfizer Products Inc. Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers, and stabilizing polymers
JP2007530596A (ja) 2004-03-26 2007-11-01 バン アンデル リサーチ インスティチュート ゲルダナマイシンおよび誘導体はガン浸潤を阻害し、新規な標的を同定する
US20050256097A1 (en) 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
CA2566713C (en) 2004-05-12 2013-01-22 Medivas, Llc Wound healing polymer compositions and methods for use thereof
US7179708B2 (en) * 2004-07-14 2007-02-20 Chung Yuan Christian University Process for fabricating non-volatile memory by tilt-angle ion implantation
WO2006034147A2 (en) 2004-09-16 2006-03-30 Abraxis Bioscience, Inc. Compositions and methods for the preparation and administration of poorly water soluble drugs
US20060067953A1 (en) 2004-09-29 2006-03-30 Conforma Therapeutics Corporation Oral pharmaceutical formulations and methods for producing and using same
RU2007120473A (ru) * 2004-11-02 2008-12-10 Конформа Терапьютикс Корпорейшн (Us) Способы лечения формы хронического лимфоцитарного лейкоза
ES2663495T3 (es) 2005-02-18 2018-04-13 Abraxis Bioscience, Llc Fármacos con hidrofobicidad mejorada para incorporación en dispositivos médicos
CA2596867A1 (en) 2005-02-28 2006-09-08 Kosan Biosciences Incorporated Pharmaceutical formulations containing 17-allylamino-17-demethoxygeldanamycin
US7608611B2 (en) 2005-03-11 2009-10-27 The Regents Of The University Of Colorado Hsp90 inhibitors, methods of making and uses therefor
WO2006110473A2 (en) 2005-04-07 2006-10-19 Conforma Therapeutics Corporation Phospholipid-based pharmaceutical formulations and methods for producing and using same
AU2006242446A1 (en) 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either in combination with a proteasome inhibitor
US7691392B2 (en) 2005-04-29 2010-04-06 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either
EP1906950A4 (en) * 2005-06-21 2008-09-24 Infinity Discovery Inc ANSAMYCIN FORMULATIONS AND METHODS OF USE
CN101213178A (zh) 2005-06-29 2008-07-02 协和发酵工业株式会社 苯环型安莎霉素衍生物
EP1909763A2 (en) 2005-07-28 2008-04-16 Isp Investments Inc. Benzoquinones of enhanced bioavailability
WO2007059116A2 (en) 2005-11-14 2007-05-24 Abraxis Bioscience, Inc. Geldanamycin derivatives and pharmaceutical compositions thereof
US20090042847A1 (en) 2005-11-23 2009-02-12 Kosan Biosciences Incorporated 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
EP1954265A2 (en) 2005-12-01 2008-08-13 Conforma Therapeutics Corporation Compositions containing ansamycin
US20070167422A1 (en) 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin

Also Published As

Publication number Publication date
WO2008073424A2 (en) 2008-06-19
MX2009006166A (es) 2009-08-26
WO2008073424A3 (en) 2008-07-31
US20090069281A1 (en) 2009-03-12
TW200833666A (en) 2008-08-16
JP2010512397A (ja) 2010-04-22
KR20090098982A (ko) 2009-09-18
BRPI0720277A2 (pt) 2014-01-28
CA2672537A1 (en) 2008-06-19
US7947670B2 (en) 2011-05-24
US8357676B2 (en) 2013-01-22
PE20081506A1 (es) 2008-12-09
EP2126548A2 (en) 2009-12-02
US8283343B2 (en) 2012-10-09
US20090062528A1 (en) 2009-03-05
WO2008073424A9 (en) 2008-10-02
AR064304A1 (es) 2009-03-25
CL2007003604A1 (es) 2009-01-23
US20080221077A1 (en) 2008-09-11
AU2007332727A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
NO20092274L (no) Ansamycinformuleringer og fremgangsmater for anvendelse derav
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
BR0313176A (pt) Composições de pirazol úteis como inibidores de gsk-3
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
NO20053972L (no) Aminosyre-avledede prodrug av propofol, sammensetninger og anvendelse derav.
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
MX2009004189A (es) Derivados que contienen sulfamoilo y sus usos.
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
WO2006066914A3 (en) Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
WO2006044497A3 (en) Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
WO2006138660A3 (en) Sphingosine kinase inhibitors
TW200604179A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
WO2006066913A3 (en) Benzamide substituted imidazo- and pyrolo-pyridines as protein kinase inhibitors
BRPI0412894A (pt) tienopiridina e furopiridina inibidores de quinases
TW200745044A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
BR0212787A (pt) Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica
NO20071314L (no) Peptidiske vasopressinreseptoragonister
BR0317284A (pt) Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno
NO20076405L (no) Anvendelse av 24-nor-UDCA
WO2007075572A3 (en) Orally active purine-based inhibitors of heat shock protein 90
NO20054346L (no) Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander
WO2003066022A3 (en) Stable pharmaceutical composition useful for treating gastrointestinal disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application